Traction for its specialty portfolio, a strong showing in the domestic market, and better regulatory compliance are positives for the country’s largest pharmaceutical (pharma) company, Sun......
Sun Pharmaceutical Industries recorded a good show for the quarter ended June this year, despite a below-par performance by Taro Pharma, its US subsidiary. At Rs 1,390 crore (Rs 13.90 billion), Sun......